Proteinuria: Increased angiotensin-receptor blocking is not the first option

Nature Reviews Nephrology

Volumn 5, Issue 7, 2009, Pages 367-368

  Ruggenenti, Piero ^a   Cravedi, Paolo ^a   Remuzzi, Giuseppe ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; RAMIPRIL; VALSARTAN; VITAMIN D DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

COMBINATION CHEMOTHERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; DRUG POTENTIATION; ENZYME INHIBITION; HEALTH CARE COST; HUMAN; PRIORITY JOURNAL; PROTEINURIA; RECEPTOR BLOCKING; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SHORT SURVEY; NOTE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; HUMANS; PROTEINURIA; TETRAZOLES;

EID: 70349241903     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2009.77     Document Type: Short Survey

References (10)

1. Burgess, E. et al. Supramaximal dose of candesartan in proteinuric renal disease. J. Am. Soc. Nephrol. doi:10.1681/ Asn.2008040416 (2009).
2. Hollemberg, N. K. et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J. Hypertens. 25, 1921-1926 (2007).
3. Remuzzi, G., Benigni, A. & Remuzzi, A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J. Clin. Invest. 116, 288-296 (2006).
4. Ruggenenti, P., Perna, A., Remuzzi, G. & Gisen Group investigators. Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney Int. 63, 2254-2261 (2003).
5. Ruggenenti, P., Perna, A., Gherardi, G., Benini, R. & Remuzzi, G. Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am. J. Kidney Dis. 35, 1155-1165 (2000).
6. Hou, F. F. et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency. J. Am. Soc. Nephrol. 18, 1889-1898 (2007).
7. Ruggenenti, P. et al. Diverse effects of increasing lisinopril doses on lipid abnormalities in chronic nephropathies. Circulation 107, 586-592 (2003).
8. Catapano, F. et al. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: Meta-analysis and metaregression. Am. J. Kidney Dis. 52, 475-485 (2008).
9. Campbell, R. et al. Effects of combined ACE inhibitor and angiotensin ii antagonist treatment in human chronic nephropathies. Kidney Int. 63, 1094-1103 (2003).
10. Ruggenenti, P. et al. Role of remission clinics in the longitudinal treatment of CKD. J. Am. Soc. Nephrol. 19, 1213-1224 (2008).